October 16, 2017
Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research
- New Funds to Support Projects in HIV Cure Discovery -
“Finding a cure for HIV is a formidable challenge to the scientific
community. Together with our newest grant recipients, all of whom have a
record of excellence in their research, we can take collective steps to
help end this devastating epidemic,” said
The following organizations and corresponding projects will receive grants from Gilead to help fund their activities (Institution/Principal Investigator/Project Name):
University of California, San Francisco, School of Medicine, Microbiology and Immunology, Chan Zuckerberg Biohub – Alexander Marson, M.D., Ph.D. – An Integrated CRISPR Platform to Discover Regulators of HIV Latency in Primary Human T Cells Institute of Human Genetics, French National Center for Scientific Research (CNRS)and University of Montpellier– Monsef Benkirane, Ph.D. – Paving the Way Towards Elimination of HIV Persistent CD4T Cell In Vivo University of Massachusetts Medical School– Abraham L. Brass, M.D., Ph.D. – A CRISPR/Cas9 Screen to Discover HIV-1 Latency Factors Frederick National Laboratory for Cancer Research, AIDS and Cancer Virus Program – Jeffrey D. Lifson, M.D. – TLR Ligand Augmented, Tissue Homing AIDS Virus-Specific Adoptive Cell Therapy to Target Viral Reservoirs Dana-Farber Cancer Institute– Joseph G. Sodroski, M.D. – Unlocking HIV-1 Env to Deplete Viral Reservoirs
The HIV cure grants program, initially announced in
For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. In further efforts to end the HIV epidemic, Gilead is conducting early-stage clinical research to identify novel agents and strategies that could play a role in eradicating HIV infection in the body.
Gilead’s corporate giving program aims to reduce health disparities,
provide access, advance medical education and support local communities.
In 2016, Funders Concerned About AIDS (FCAA) recognized Gilead as the
leading corporate global funder of HIV/AIDS programs, and second overall
For more information on
View source version on businesswire.com: http://www.businesswire.com/news/home/20171016005352/en/
Gilead Sciences, Inc.
Sung Lee, 650-524-7792
Brent Tippen, 650-653-9354